Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus ISOCLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus ISOCLOR.
BROMPHENIRAMINE MALEATE vs ISOCLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Chlorpheniramine is an antihistamine (H1-receptor antagonist) that blocks the action of histamine, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors, causing vasoconstriction in the nasal mucosa.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
Oral: 1 tablet (chlorpheniramine 4 mg / pseudoephedrine 60 mg) every 4-6 hours, not to exceed 4 tablets per 24 hours.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Approximately 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily renal; approximately 60-70% of a dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination